1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. GLOBAL PHARMACOVIGILANCE MARKET BY CLINICAL TRIAL PHASE
5.1. Introduction
5.2. Preclinical
5.2.1. Market Opportunities and Trends
5.2.2. Growth Prospects
5.2.3. Geographic Lucrativeness
5.3. Phase I
5.3.1. Market Opportunities and Trends
5.3.2. Growth Prospects
5.3.3. Geographic Lucrativeness
5.4. Phase II
5.4.1. Market Opportunities and Trends
5.4.2. Growth Prospects
5.4.3. Geographic Lucrativeness
5.5. Phase III
5.5.1. Market Opportunities and Trends
5.5.2. Growth Prospects
5.5.3. Geographic Lucrativeness
5.6. Phase IV
5.6.1. Market Opportunities and Trends
5.6.2. Growth Prospects
5.6.3. Geographic Lucrativeness
6. GLOBAL PHARMACOVIGILANCE MARKET BY SERVICE PROVIDER
6.1. Introduction
6.2. Contract Outsourcing
6.2.1. Market Opportunities and Trends
6.2.2. Growth Prospects
6.2.3. Geographic Lucrativeness
6.3. In-house
6.3.1. Market Opportunities and Trends
6.3.2. Growth Prospects
6.3.3. Geographic Lucrativeness
7. GLOBAL PHARMACOVIGILANCE MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceuticals
7.2.1. Market Opportunities and Trends
7.2.2. Growth Prospects
7.2.3. Geographic Lucrativeness
7.3. Biotechnology Companies
7.3.1. Market Opportunities and Trends
7.3.2. Growth Prospects
7.3.3. Geographic Lucrativeness
7.4. Medical Device Manufacturers
7.4.1. Market Opportunities and Trends
7.4.2. Growth Prospects
7.4.3. Geographic Lucrativeness
7.5. Others
7.5.1. Market Opportunities and Trends
7.5.2. Growth Prospects
7.5.3. Geographic Lucrativeness
8. GLOBAL PHARMACOVIGILANCE MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Clinical Trial Phase
8.2.2. By Service Provider
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.1.1. Market Opportunities and Trends
8.2.4.1.2. Growth Prospects
8.2.4.2. Canada
8.2.4.2.1. Market Opportunities and Trends
8.2.4.2.2. Growth Prospects
8.2.4.3. Mexico
8.2.4.3.1. Market Opportunities and Trends
8.2.4.3.2. Growth Prospects
8.3. South America
8.3.1. By Clinical Trial Phase
8.3.2. By Service Provider
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.1.1. Market Opportunities and Trends
8.3.4.1.2. Growth Prospects
8.3.4.2. Argentina
8.3.4.2.1. Market Opportunities and Trends
8.3.4.2.2. Growth Prospects
8.3.4.3. Others
8.3.4.3.1. Market Opportunities and Trends
8.3.4.3.2. Growth Prospects
8.4. Europe
8.4.1. By Clinical Trial Phase
8.4.2. By Service Provider
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. Germany
8.4.4.1.1. Market Opportunities and Trends
8.4.4.1.2. Growth Prospects
8.4.4.2. France
8.4.4.2.1. Market Opportunities and Trends
8.4.4.2.2. Growth Prospects
8.4.4.3. United Kingdom
8.4.4.3.1. Market Opportunities and Trends
8.4.4.3.2. Growth Prospects
8.4.4.4. Italy
8.4.4.4.1. Market Opportunities and Trends
8.4.4.4.2. Growth Prospects
8.4.4.5. Spain
8.4.4.5.1. Market Opportunities and Trends
8.4.4.5.2. Growth Prospects
8.4.4.6. Others
8.4.4.6.1. Market Opportunities and Trends
8.4.4.6.2. Growth Prospects
8.5. Middle East and Africa
8.5.1. By Clinical Trial Phase
8.5.2. By Service Provider
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.1.1. Market Opportunities and Trends
8.5.4.1.2. Growth Prospects
8.5.4.2. UAE
8.5.4.2.1. Market Opportunities and Trends
8.5.4.2.2. Growth Prospects
8.5.4.3. South Africa
8.5.4.3.1. Market Opportunities and Trends
8.5.4.3.2. Growth Prospects
8.5.4.4. Others
8.5.4.4.1. Market Opportunities and Trends
8.5.4.4.2. Growth Prospects
8.6. Asia Pacific
8.6.1. By Clinical Trial Phase
8.6.2. By Service Provider
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.1.1. Market Opportunities and Trends
8.6.4.1.2. Growth Prospects
8.6.4.2. India
8.6.4.2.1. Market Opportunities and Trends
8.6.4.2.2. Growth Prospects
8.6.4.3. Japan
8.6.4.3.1. Market Opportunities and Trends
8.6.4.3.2. Growth Prospects
8.6.4.4. South Korea
8.6.4.4.1. Market Opportunities and Trends
8.6.4.4.2. Growth Prospects
8.6.4.5. Taiwan
8.6.4.5.1. Market Opportunities and Trends
8.6.4.5.2. Growth Prospects
8.6.4.6. Thailand
8.6.4.6.1. Market Opportunities and Trends
8.6.4.6.2. Growth Prospects
8.6.4.7. Indonesia
8.6.4.7.1. Market Opportunities and Trends
8.6.4.7.2. Growth Prospects
8.6.4.8. Others
8.6.4.8.1. Market Opportunities and Trends
8.6.4.8.2. Growth Prospects
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Cognizant
10.2. Sciformix (Covance)
10.3. IQVIA
10.4. APCER Life Sciences, Inc.
10.5. Navitas Life Sciences
10.6. BioClinica
10.7. Accenture
10.8. ArisGlobal
10.9. Capgemini
10.10. FMD K&L Inc.